Straits Times Index
3,072.99 -11.71 (-0.38%) S&P 500
4,550.58 -4.31 (-0.09%) Dow
35,430.42 +13.44 (+0.04%) Nasdaq
14,258.49 -23.27 (-0.16%) Bitcoin USD
37,687.27 -360.00 (-0.95%) CMC Crypto 200
778.70 -6.80 (-0.87%)
UroGen Pharma Ltd. (0XOD.L)
- Insider Monkey
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […]
- Business Wire
UroGen Pharma Reports Third Quarter 2023 Financial Results
PRINCETON, N.J., November 14, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments.
- Business Wire
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
PRINCETON, N.J., November 13, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, will highlight data from two key Phase 3 trials evaluating UGN-102, an investigational treatment in development for LG-IR-NMIBC at the 2023 Society of Urologic Oncology (SUO) annual meeting, November 28-December 1 in Washington D.C. These data presentations further UroGen’s mission of developing and comme
